ATRA
Atara Biotherapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$88.30M
P/E Ratio
—
EPS
$-1.22
Beta
-0.29
52W High
$19.14
52W Low
$3.92
50-Day MA
$6.07
200-Day MA
$10.15
Dividend Yield
—
Profit Margin
-40.90%
Forward P/E
232.56
PEG Ratio
0.00
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $23.14M |
| Gross Profit (TTM) | $-2.70M |
| EBITDA | $7.65M |
| Operating Margin | -653.00% |
| Return on Equity | -2015.00% |
| Return on Assets | 11.10% |
| Revenue/Share (TTM) | $1.73 |
| Book Value | $-4.38 |
| Price-to-Book | 16.14 |
| Price-to-Sales (TTM) | 3.82 |
| EV/Revenue | 3.965 |
| EV/EBITDA | 2.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.50% |
| Shares Outstanding | $9.01M |
| Float | $4.74M |
| % Insiders | 16.66% |
| % Institutions | 48.77% |
Historical Volatility
HV 10-Day
67.17%
HV 20-Day
61.79%
HV 30-Day
71.45%
HV 60-Day
101.39%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($13.67 target)
2
Buy1
Hold1
SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026